Literature DB >> 8843279

Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

T Kocagöz1, C J Hackbarth, I Unsal, E Y Rosenberg, H Nikaido, H F Chambers.   

Abstract

To characterize mechanisms of resistance to fluoroquinolones by Mycobacterium tuberculosis, mutants of strain H37Ra were selected in vitro with ofloxacin. Their quinolone resistance-determining regions for gyrA and gyrB were amplified and sequenced to identify mutations in gyrase A or B. Three types of mutants were obtained: (i) one mutant (TKp1) had no mutations in gyrA or gyrB; (ii) mutants that had single missense mutations in gyrA, and (iii) mutants that had two missense mutations resulting in either two altered gyrase A residues or an altered residue in both gyrases A and B. The TKp1 mutant had slightly reduced levels of uptake of [14C]norfloxacin, which was associated with two- to fourfold increases in the MICs of ofloxacin, ciprofloxacin, and sparfloxacin. Gyrase mutations caused a much greater increase in the MICs of fluoroquinolones. For mutants with single gyrA mutations, the increases in the MICs were 4- to 16-fold, and for mutants with double gyrase mutations, the MICs were increased 32-fold or more compared with those for the parent. A gyrA mutation in TKp1 secondary mutants was associated with 32- to 128-fold increases in the MICs of ofloxacin and ciprofloxacin compared with the MICs for H37Ra and an eight-fold increase in the MIC of sparfloxacin. Sparfloxacin was the most active fluoroquinolone tested. No sparfloxacin-resistant single-step mutants were selected at concentrations of > 2.5 micrograms/ml, and high-level resistance (i.e., MIC, > and = 5 micrograms/ml) was associated with two gyrase mutations. Mutations in gyrB and possibly altered levels of intracellular accumulation of drug are two additional mechanisms that may be used by M. tuberculosis in the development of fluoroquinolone resistance. Because sparfloxacin is more active in vitro and selection of resistance appears to be less likely to occur, it may have important advantage over ofloxacin or ciprofloxacin for the treatment of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843279      PMCID: PMC163415     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction.

Authors:  M Oram; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 2.  Molecular basis of bacterial outer membrane permeability.

Authors:  H Nikaido; M Vaara
Journal:  Microbiol Rev       Date:  1985-03

Review 3.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods.

Authors:  C N Lee; L B Heifets
Journal:  Am Rev Respir Dis       Date:  1987-08

5.  Outer membrane of Salmonella typhimurium. Transmembrane diffusion of some hydrophobic substances.

Authors:  H Nikaido
Journal:  Biochim Biophys Acta       Date:  1976-04-16

6.  Detection of Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified procedure.

Authors:  T Kocagöz; E Yilmaz; S Ozkara; S Kocagöz; M Hayran; M Sachedeva; H F Chambers
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

7.  Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.

Authors:  V Lalande; C Truffot-Pernot; A Paccaly-Moulin; J Grosset; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.

Authors:  Y Wang; W M Huang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins.

Authors:  P Hallett; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

10.  Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus.

Authors:  Y X Furet; J Deshusses; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more
  44 in total

1.  Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes.

Authors:  Jean-Noël Dauendorffer; Isabelle Guillemin; Alexandra Aubry; Chantal Truffot-Pernot; Wladimir Sougakoff; Vincent Jarlier; Emmanuelle Cambau
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

Review 2.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

3.  Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes.

Authors:  Corinne Surcouf; Seiha Heng; Catherine Pierre-Audigier; Véronique Cadet-Daniel; Amine Namouchi; Alan Murray; Brigitte Gicquel; Bertrand Guillard
Journal:  BMC Infect Dis       Date:  2011-09-28       Impact factor: 3.090

4.  Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis.

Authors:  Xiaoyou Chen; Fanrong Kong; Qinning Wang; Chuanyou Li; Jianyuan Zhang; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

Review 5.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 6.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

7.  Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Authors:  Florence Brossier; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

8.  Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India.

Authors:  Kanchan Ajbani; Camilla Rodrigues; Shubhada Shenai; Ajita Mehta
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

9.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

10.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.